1968
DOI: 10.1259/0007-1285-41-485-391
|View full text |Cite
|
Sign up to set email alerts
|

The risk of bone cancer in man from internally deposited radium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

1970
1970
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 7 publications
0
5
0
Order By: Relevance
“…However, its coveted effects are tempered by lower body temperature and smaller body size [154]. While CR diminishes the risk of carcinogenesis by lengthening the latent period, radiation acts in the exact opposite manner, causing excess cancers by diminishing the latent period [126,155]. Similarly, while CR appears to suppress age-related increases in ROS, apoptosis and inflammation, IR generally enhances these effects [16,53, 64,65,157].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, its coveted effects are tempered by lower body temperature and smaller body size [154]. While CR diminishes the risk of carcinogenesis by lengthening the latent period, radiation acts in the exact opposite manner, causing excess cancers by diminishing the latent period [126,155]. Similarly, while CR appears to suppress age-related increases in ROS, apoptosis and inflammation, IR generally enhances these effects [16,53, 64,65,157].…”
Section: Discussionmentioning
confidence: 99%
“…Female U.S. radium-dial painters were first exposed to 226,228 Ra at 20±5 years of age; and bone sarcomas appeared on average 27±14 years later [125]. The higher the radium activity (and dose), beyond a threshold value of 2 MBq, the shorter the latent period [126]. At low doses, the radiation-induced aging effect and the reduction in the latent period (from exposure to the cancer's appearance) are small.…”
Section: Comparison Of Aging and Radiation Effectsmentioning
confidence: 99%
“…For intravenous administration in cancer therapy, the risks of carcinogenesis also depend highly on the amount administered and radiation dose to the most affected organs and tissues. Although scientific experience with injected 223 RaCl 2 is relatively recent (Parker et al , 2013), a vast amount of information is known on the carcinogenic risks associated with cationic 224 Ra, 226 Ra, and 228 Ra in the incidence of soft-tissue sarcoma, osteosarcoma, sinus/ mastoid carcinoma, and leukemia induction (Evans, 1967; Evans et al , 1969; 1972; Finkel et al , 1969; Rowland, 1994; Spiess et al , 1962; Van Alyea, 1939). The short physical half-lives of therapeutic alpha emitters (from 46 min for 213 Bi to 11.4 days for 223 Ra) limit the risks normally associated with long-term retention but greatly magnify the localized dose rate.…”
Section: Radiobiology and Bioeffect Modelingmentioning
confidence: 99%
“…Hems (1967) found that the data could be described by a linear nonthreshold function that predicted a tumor risk of 1 in 20 at an initial radium content of 100 µCi. Evans et al (1968), in a letter to the editor of the journal that published Hems's paper, challenged the manner in which the data had been selected from the quoted sources. Hems, for example, selected only portions of the Finkel et al (1964) data, omitting 117 cases below 0.1 µCi, where no tumors were seen.…”
Section: Risk Estimates For Radium-induced Malignanciesmentioning
confidence: 99%